Sterne Agee CRT Reiterates Buy rating on Ulta Salon (ULTA) Following Q1
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Cowen Raises Price Target Following Ulta Salon's (ULTA) 11c EPS Beat
May 29, 2015 7:00 AM EDTCowen reiterates an Outperform rating on ULTA Salon (NASDAQ: ULTA), and raised the price target to $178.00 (from $170.00), following 1Q results. ULTA reported 1Q EPS of $1.04, significantly ahead of Cowen's $0.91 estimate. Reported sales were $868mm or vs. Cowen's $843mm estimate.
Analyst Oliver Chen commented, "ULTA's +11c EPS beat vs. St on healthy traffic & loyalty program gains is encouraging for sustainability of... More
After-Hours Stock Movers 05/28: (HRTX) (STML) (GME) (BLOX) Higher; (DECK) (CLLS) Lower (more...)
May 28, 2015 5:51 PM EDTHeron Therapeutics, Inc. (Nasdaq: HRTX) 39.8% HIGHER; announced positive, top-line results from its recently completed Phase 3 MAGIC study. MAGIC evaluated the efficacy and safety of the Companys 5-HT3 receptor antagonist product candidate SUSTOL® (granisetron injection, extended release) as part of a three-drug regimen with the intravenous (IV) neurokinin-1 (NK1) receptor antagonist fosaprepitant and the IV corticosteroid dexamethasone for the prevention of delayed-onset chemotherapy-induced nausea and vomiting (CINV) following administration of highly emetogenic chemotherapy (HEC) agents.
Ulta Salon (ULTA) Tops Q1 EPS by 11c, Comps Increase 11.4%, Updates Guidance
May 28, 2015 4:06 PM EDTUlta Salon (NASDAQ: ULTA) reported Q1 EPS of $1.04, $0.11 better than the analyst estimate of $0.93. Revenue for the quarter came in at $868.1 million versus the consensus estimate of $845.83 million. Comparable sales (sales for stores open at least 14 months and e-commerce sales) increased 11.4% compared to an increase of 8.7% in the... More
Trading Radar for 5/28: Avago (AVGO), OmniVision (OVTI), GameStop (GME), Express (EXPR), Dangdang (DANG) Report
May 27, 2015 2:47 PM EDTThe Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Economics:
8:30am EDT
Earnings:
Abercrombie & Fitch (NYSE: ANF) - consensus loss $0.34
Agilysys, Inc. (Nasdaq: AGYS) - consensus loss $0.04
American Superconductor (Nasdaq: AMSC) - consensus loss $0.70
Auris Medical Holding (Nasdaq: EARS) - consensus loss $0.22
China Xiniya... More
